Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Depoxythilone - Beijing Biostar Technologies

Next Previous
Drug Profile

Depoxythilone - Beijing Biostar Technologies

Alternative Names: UTD-1; UTD-2; Utidelone; Utidelone - Beijing Biostar Technologies

Latest Information Update: 18 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Biostar Technologies; BioStar Pharmaceuticals
  • Developer Beijing Biostar Technologies; BioStar Pharmaceuticals; Henan Cancer Hospital
  • Class Antineoplastics; Epothilones
  • Mechanism of Action Mitosis inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Breast cancer; Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase III Non-small cell lung cancer
  • Phase II/III Fallopian tube cancer; Gastric cancer; Oesophageal cancer; Peritoneal cancer
  • Phase II Colorectal cancer; HER2 negative breast cancer; Small cell lung cancer; Solid tumours

Most Recent Events

  • 12 Sep 2025 Phase-II/III clinical trials in Fallopian tube cancer (Late-stage disease, Second-line therapy or greater) (PO) (NCT07044349)
  • 12 Sep 2025 Phase-II/III clinical trials in Oesophageal cancer (Late-stage disease, Second-line therapy or greater) (PO) (NCT07044349)
  • 12 Sep 2025 Phase-II/III clinical trials in Peritoneal cancer (Late-stage disease, Second-line therapy or greater) (PO) (NCT07044349)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top